Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2015 09:25 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases

Company is Currently Evaluating Human Clinical Data From Previous Studies Supporting Clinical Development Program Expansion Beyond Treatment of Adult Burns Into Pediatric Burns Published Data...
October 01, 2015 07:32 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible

SAN FRANCISCO and GENEVA, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates for orphan...
September 14, 2015 10:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion

SAN FRANCISCO and GENEVA, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in...
September 03, 2015 07:05 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Results of Annual Meeting

SAN FRANCISCO and GENEVA, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 26, 2015 12:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Moves Annual Meeting Date Forward to September 2, 2015

SAN FRANCISCO and GENEVA, Aug. 26, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 20, 2015 08:35 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF

SAN FRANCISCO and GENEVA, Aug. 20, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 17, 2015 08:05 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Reports Second Quarter 2015 Financial Results and Business Overview

SAN FRANCISCO and GENEVA, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 07, 2015 17:05 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Adjournment of Annual Meeting

SAN FRANCISCO and GENEVA, Aug. 7, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 05, 2015 08:50 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID

Latest preclinical data in the peer-reviewed journal 'Movement Disorders' support previous nonclinical and clinical findings that eltoprazine is effective against Parkinson's Disease L-dopa...
August 03, 2015 17:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Adjournment of Annual Meeting

SAN FRANCISCO and GENEVA, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...